Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company trimmed its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 6.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 100,311 shares of the medical equipment provider’s stock after selling 7,441 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Lantheus were worth $8,974,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Wilmington Savings Fund Society FSB purchased a new position in Lantheus in the third quarter worth approximately $25,000. Kestra Investment Management LLC purchased a new position in shares of Lantheus during the 4th quarter worth $27,000. Summit Securities Group LLC acquired a new stake in shares of Lantheus during the 4th quarter worth about $37,000. UMB Bank n.a. raised its holdings in Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after buying an additional 134 shares during the period. Finally, World Investment Advisors LLC acquired a new position in Lantheus in the third quarter valued at about $60,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Insider Buying and Selling

In other news, Director Mary Anne Heino sold 53,107 shares of the company’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares of the company’s stock, valued at approximately $41,551,645.65. This represents a 10.76 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the sale, the chief financial officer now directly owns 113,860 shares in the company, valued at $11,445,207.20. This trade represents a 8.07 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 63,109 shares of company stock worth $6,016,046. Corporate insiders own 1.50% of the company’s stock.

Lantheus Stock Down 0.7 %

Lantheus stock opened at $107.98 on Tuesday. The company’s 50 day moving average is $100.19 and its two-hundred day moving average is $94.82. The firm has a market cap of $7.39 billion, a PE ratio of 17.97 and a beta of 0.23. Lantheus Holdings, Inc. has a 52-week low of $74.28 and a 52-week high of $126.89.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). The company had revenue of $391.11 million for the quarter, compared to analysts’ expectations of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. On average, equities research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on LNTH. B. Riley reduced their price target on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research note on Friday, March 21st. JMP Securities restated a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. Finally, Truist Financial lifted their price objective on Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $134.33.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.